Noile-Immune Biotech Inc. Logo

Noile-Immune Biotech Inc.

Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.

4893 | T

Overview

Corporate Details

ISIN(s):
JP3759560000
LEI:
Country:
Japan
Address:
港区芝大門二丁目12番10号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Noile-Immune Biotech Inc. is a clinical-stage biotechnology company focused on the development and commercialization of novel cancer immunotherapies. The company specializes in CAR-T cell therapy aimed at treating solid tumors, a significant challenge in oncology. Its core is the proprietary PRIME (Proliferation-Inducing and Migration-Enhancing) technology, a next-generation platform designed to augment the efficacy of CAR-T cells. Noile-Immune advances its therapeutic pipeline through in-house research and strategic partnerships with academic and corporate entities, with the mission to create transformative treatments for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-08 09:15
Report Publication Announcement
確認書
Japanese 8.1 KB
2025-08-08 09:14
Interim Report
半期報告書-第11期(2025/01/01-2025/12/31)
Japanese 143.9 KB
2025-04-01 09:11
Post-Annual General Meeting Information
臨時報告書
Japanese 23.5 KB
2025-03-28 05:44
Registration Form
確認書
Japanese 8.2 KB
2025-03-28 05:43
Governance Information
内部統制報告書-第10期(2024/01/01-2024/12/31)
Japanese 21.2 KB
2025-03-28 05:42
Annual Report
有価証券報告書-第10期(2024/01/01-2024/12/31)
Japanese 4.1 MB
2024-10-15 05:07
Report Publication Announcement
訂正確認書
Japanese 8.2 KB
2024-10-15 05:06
Interim Report
訂正半期報告書-第10期(2024/01/01-2024/12/31)
Japanese 124.4 KB
2024-08-13 05:02
Interim Report
半期報告書-第10期(2024/01/01-2024/12/31)
Japanese 150.3 KB
2024-08-13 05:00
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-05-14 10:07
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-05-14 10:05
Quarterly Report
四半期報告書-第10期第1四半期(2024/01/01-2024/03/31)
Japanese 117.7 KB
2024-04-02 06:49
Post-Annual General Meeting Information
臨時報告書
Japanese 22.2 KB
2024-03-29 06:19
Registration Form
確認書
Japanese 8.2 KB
2024-03-29 06:18
Governance Information
内部統制報告書-第9期(2023/01/01-2023/12/31)
Japanese 21.2 KB

Automate Your Workflow. Get a real-time feed of all Noile-Immune Biotech Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Noile-Immune Biotech Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Noile-Immune Biotech Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CIZZLE BIOTECHNOLOGY HOLDINGS PLC Logo
Developing a CIZ1B biomarker blood test for the early detection of lung cancer.
United Kingdom
CIZ
Clear Channel Outdoor Holdings, Inc. Logo
An OOH ad platform connecting brands to consumers via digital billboards and data analytics.
United States of America
CCO
CODEXIS, INC. Logo
Engineering high-performance enzymes for pharma, diagnostics, and life science manufacturing.
United States of America
CDXS
Cogent Biosciences, Inc. Logo
Developing precision small molecule therapies for cancers, autoimmune, and rare diseases.
United States of America
COGT
COMPASS Pathways plc Logo
Developing psilocybin therapies for severe mental health challenges like TRD and PTSD.
United States of America
CMPS
COMSCORE, INC. Logo
Cross-platform audience measurement and media analytics for advertisers, publishers, and agencies.
United States of America
SCOR
COPRO-HOLDINGS. Co., Ltd. Logo
Dispatches technical personnel to Japan's construction & plant industries.
Japan
7059
Corbus Pharmaceuticals Holdings, Inc. Logo
Clinical-stage oncology company developing targeted therapies like ADCs for cancer and obesity.
United States of America
CRBP
Corvus Pharmaceuticals, Inc. Logo
Develops novel, targeted therapies for immune diseases and cancer.
United States of America
CRVS
Coya Therapeutics, Inc. Logo
Developing Treg-modulating therapies for neurodegenerative and autoimmune diseases.
United States of America
COYA

Talk to a Data Expert

Have a question? We'll get back to you promptly.